Introduction
Many patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa and/or Burkholderia cepacia pulmonary infection require frequent intermittent intravenous antibiotic therapy for treatment of infective exacerbations.
The use of intravenous cannulae is associated with a high incidence of thrombophlebitis (l), and repeat venepuncture of peripheral veins often results in venous thrombosis. Difficult venous access and needle phobia in some patients pose additional problems. Totally implantable venous access devices (TIVADs) provide an alternative means of venous access and have been used successfully in oncology patients requiring intermittent chemotherapy for some years (2,3). The use of TIVADs in patients with CF was first described in 1986 (4). Since then, only a limited number of reports have been published on the use of such devices in this group of patients (5-9). Experience has ranged from 8 months (5) where there were few problems associated with TIVADs, through to 6 years where there were problems with catheter occlusion, venous thrombosis and infection (6) (7) (8) (9) . An audit of the use of such devices was undertaken in the authors' patients in the Adult Cystic Fibrosis Centre over a period of 8 yr. was 20 years (range 1540 years) and their median FEV, at implantation was 28% of predicted (range 1 l-94%).
All but two patients in the PC group and all but one patient in the PP group had their devices implanted under general anaesthesia. The routes of catheter insertion are summarized in Table 1 .
During the study period, the time during which the PCs were in place and remained functional ranged from 99 to 2219 days (median 1146 days); the corresponding figures for PPs were 7 to 1054 days (median 248 days). There were 50 complications over a total of 25 824 catheter functional days (Table 2) ; a complication rate of one every 516 days of catheter function (PC: one episode in 625 days; PP: one episode in 207 days).
One patient, who had a PC implanted under local anaesthesia and sedation, deteriorated immediately following implantation, probably as a result of over-sedation. She was intubated and required a brief period of mechanical ventilation but made a full recovery.
All patients had post-operative chest radiographs performed and no pneumothorax was identified.
Late complications can be divided into infective or mechanical. There were five episodes of infection in four patients (Table 2) , including three episodes of site infection, which is defined as positive swabs from the needle puncture site with associated signs of inflammation.
All such episodes resolved following intravenous antibiotic therapy.
One patient developed fungaemia with pyrexia and pain at the PC site 53 months following implantation; culture of blood taken from the peripheral vein and from the portal revealed growth of Candida parapsilosis. The PC was removed and she recovered fully following a 3-week course of intravenous amphotericin. A second patient presented with episodes of rigor and headache 4 months following implantation.
Blood culture taken from his peripheral vein and from the portal of his PP revealed growth of Pseudomonas aeruginosa. The device was removed and he recovered with intravenous antibiotic therapy.
Catheter occlusion is relatively common and is presumably due to thrombus formation within or at the tip of the catheter. This complication usually resolved with the use of heparin or urokinase. There were two patients with venous thrombosis, confirmed on venogram, requiring removal of the devices and a period of anticoagulant therapy. Another patient had a thrombus at the tip of her PC identified by two-dimensional echocardiogram 5 yr following implantation.
This was complicated by pulmonary embolism. She recovered fully following thrombolytic therapy and is now on long-term warfarin treatment. Her PC remains functional.
During the study period, six PCs and four PPs were removed as a result of complications (Table 3) . One PC was removed after the patient received a successful heart-lung transplant. Seven patients who had TIVADs implanted died during the study period, but none of the deaths was related to their devices.
All surviving patients with TIVADs in situ at present or at some stage in the past were interviewed by telephone during the last week of April 1995. Patients were asked to rate their overall satisfaction with the devices (1 = totally dissatisfied; 5 = totally satisfied). Patients in both the PC and the PP group expressed a high degree of satisfaction with their . devices, with PCs and PPs having median ratings of 4.5 and 4.0, respectively. All patients would undergo another TIVAD insertion in the future although, for cosmetic reasons, three out of 11 patients in the PC group and four out of five patients in the PP group preferred to have a PP implanted.
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The rest of the patients expressed no preference.
Discussion
Totally implantable venous access devices have been used in oncology since 1982 and have a lower incidence of infection and thrombosis compared to external systems (2,3). These devices have the additional advantages of being convenient to use and easy to manage. Since the use of a PC was first described in a patient with CF in 1986 (4), only a limited number of reports have been published on the use of such devices in this group of patients, particularly with the use of the PP devices which were introduced in 1988 (10). In contrast to most series (5, 7, 8) , most of the patients in the present study had their devices implanted under general anaesthesia. General anaesthesia is preferred by the authors' surgeon because the implantation procedure is less likely to be disturbed by patients' activities such as coughing and movement. The patients tolerated the procedure well despite the severity of the pulmonary disease. No pneumothorax was identified, compared to a rate of 4.4% reported by Morris et al. (8) . This is likely to be the result of a relatively smaller number of cases with the subclavian vein as the route of catheter cannulation in the present series. The occurrence of pneumothorax would be particularly undesirable in this group of patients with existing severe lung impairment. There were 50 episodes of complications in 33 devices over a period of 8 yr. Catheter occlusion, presumably due to the presence of small thrombi within or at the tip of the catheter, accounted for a large proportion of the complication episodes. In the study centre, a 30 ml syringe containing 5 ml of heparinized saline (10 IU ml -') is used to irrigate and aspirate the device alternatively when the authors attempt to clear small thrombi. On the rare occasions when occlusion persists, 0.2 ml of urokinase (5000 IU ml -') is injected into the device and aspiration of the clot is attempted after 20 min. These steps are repeated until the catheter clears.
Three episodes of venous thrombosis were confirmed during the use of 33 devices over a period of 8 yr, compared with three episodes of superior vena caval syndrome or venous thrombosis in 22 TIVADs over a 6-yr period as reported by Sola et al. (9) . The recognized risk of thrombotic events related to the use of TIVADs leads Sola et al. to recommend the prophylactic use of aspirin in all CF patients with such devices who have no evidence of liver disease or bleeding problems(g).
One of the present authors' patients had pulmonary embolism from the thrombus, a complication not previously reported with the use of TIVADs in CF patients.
The present infection rate of five episodes in 33 devices (15.2%) over a period of 8 yr is comparable to the reported 17.6% in 68 devices over 4.5 yr (8). The present series included a patient with fungaemia. Risk factors for this complication include: severe underlying lung disease; acute infective exacerbation, malnutrition, frequent use of broad spectrum antibiotics; parental nutrition; and diabetes mellitus. Removal of the device in such a situation is essential (11).
In common with other studies, the authors found that PCs provide safe and reliable long-term venous access for this group of patients. The relatively high complication rates and short functional time related to PPs is in common with Conway et al.'s experience with 65 PPs inserted in 57 patients which was published in an abstract (12). Portal protrusion was a significant problem, accounting for four of the 10 removals including two of the four PPs removed. This complication may be related to the relatively small amount of subcutaneous tissue in these usually poorly nourished patients (8).
Totally implantable venous access devices were generally well accepted by patients. Despite being well informed of the shorter functional time and the higher complication rates of PPs, most patients opted In the authors' centre, TIVADs are recommended to selected patients in whom their use quickly becomes a matter of simple routine. These devices provide safe, effective and convenient means of venous access for patients who require intermittent antibiotic therapy and are prepared to care for such devices over long periods. In the selection of a device, patient preference is a strong factor which may sometimes over-ride choice based solely on functional efficiency. It is essential that patients are fully informed regarding the merits of various devices, and that proper comparisons are made between devices as new ones are introduced into clinical practice. 
